Shares of DRI Healthcare Trust (TSE:DHT.UN – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the six analysts that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year target price among analysts that have covered the stock in the last year is C$17.94.
Several research firms have recently weighed in on DHT.UN. CIBC decreased their price target on DRI Healthcare Trust from C$19.50 to C$18.00 and set an “outperform” rating for the company in a research note on Thursday, December 12th. Raymond James decreased their target price on DRI Healthcare Trust from C$23.00 to C$22.00 in a report on Wednesday, November 13th. Finally, Scotiabank upped their price target on shares of DRI Healthcare Trust from C$21.00 to C$22.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 8th.
View Our Latest Analysis on DRI Healthcare Trust
DRI Healthcare Trust Price Performance
About DRI Healthcare Trust
DRI Healthcare Trust focuses on managing and growing a portfolio of pharmaceutical royalties. It owns a portfolio of 18 royalties derived from the sale of 14 various pharmaceutical products that focuses on eight therapeutic areas. The company was incorporated in 2020 and is headquartered in Toronto, Canada.
Further Reading
- Five stocks we like better than DRI Healthcare Trust
- How is Compound Interest Calculated?
- S&P 500 ETFs: Expense Ratios That Can Boost Your Long-Term Gains
- Find and Profitably Trade Stocks at 52-Week Lows
- How AI Implementation Could Help MongoDB Roar Back in 2025
- Pros And Cons Of Monthly Dividend Stocks
- Hedge Funds Boost Oil Positions: Is a Major Rally on the Horizon?
Receive News & Ratings for DRI Healthcare Trust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DRI Healthcare Trust and related companies with MarketBeat.com's FREE daily email newsletter.